Skip to main content

NGM Biopharmaceuticals Inc

NGMDelisted Apr 5, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001426332

NGM Biopharmaceuticals Inc was delisted on Apr 5, 2024; its insiders filed their last Form 4 on Apr 8, 2024; 75 institutions reported holding it in 13F filings for Q1 2024, worth $55.1M in total; no superinvestor held it.

13F holders, Q1 2021

Institutional positions in NGM Biopharmaceuticals Inc as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
108
No complete 13F data for Q4 2020
Shares held
43.0M
No complete 13F data for Q4 2020
Total value
$1.25B
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting NGM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 108 institutions
Q1 2021: 108 institutionsQ2 2021: 107 institutionsQ3 2021: 121 institutionsQ4 2021: 119 institutionsQ1 2022: 114 institutionsQ2 2022: 124 institutionsQ3 2022: 128 institutionsQ4 2022: 125 institutionsQ1 2023: 123 institutionsQ2 2023: 106 institutionsQ3 2023: 95 institutionsQ4 2023: 83 institutionsQ1 2024: 75 institutionsQ2 2024: 0 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ1 2021: $1.25B
Q1 2021: $1.25BQ2 2021: $849.7MQ3 2021: $951.2MQ4 2021: $833.5MQ1 2022: $732.8MQ2 2022: $607.3MQ3 2022: $689.9MQ4 2022: $248.9MQ1 2023: $200.4MQ2 2023: $124.4MQ3 2023: $50.6MQ4 2023: $35.3MQ1 2024: $55.1MQ2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding NGM and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20240$0
Q1 202475$55.1M
Q4 202383$35.3M
Q3 202395$50.6M
Q2 2023106$124.4M
Q1 2023123$200.4M
Q4 2022125$248.9M
Q3 2022128$689.9M
Q2 2022124$607.3M
Q1 2022114$732.8M
Q4 2021119$833.5M
Q3 2021121$951.2M
Q2 2021107$849.7M
Q1 2021108$1.25B

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding NGM Biopharmaceuticals Inc.

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding NGM in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Euclidean Capital LLC1,493,349$43.4M14.53%––
Greenspring Associates, LLC1,573,357$45.7M36.38%––
Point72 Asset Management, L.P.2,175,000$63.2M0.32%––
Vanguard Group Inc2,241,448$65.2M0.00%––
Redmile Group, LLC2,751,815$80.0M1.13%––
BlackRock Inc.2,764,580$80.4M0.00%––
Rho Capital Partners Inc3,766,666$109.5M10.53%––
The Column Group LLC15,396,116$447.6M42.88%––